Acute Leukemia
S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
Published in Blood Weekly, December 13th, 2007
SB1317 is designed to selectively inhibit major signalling pathways involving Flt3 and CDK, which impact disease progression in acute leukemias. Flt3 mutations are the most frequent genetic alterations reported in acute myeloid leukemia (AML) patients and are associated with a poor prognosis. In addition, over-expression of wild type Flt3 has been found in acute lymphoblastic leukemia (ALL) patients. Cyclin-dependent kinases or CDKs play important roles in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2007-12-13)
More Articles from Blood Weekly
- Heart Attack
Red blood cell transfusions under scrutiny - Acute Myeloid Leukemia
St. Jude Researchers Identify Key Genetic Trigger of Acute Myeloid Leukemia - Acute Promyelocytic Leukemia
Research from Nagoya University, Medical Department provide new insights into acute promyelocytic leukemia - Acute Promyelocytic Leukemia
Studies conducted at University of Sao Paulo on acute promyelocytic leukemia recently published - Angiogenesis
Studies from S. Molica and co-authors have provided new information about angiogenesis - Bacteremia
Investigators at University of Barcelona zero in on bacteremia - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
